June 2026 FDA Recall Glucagon by Lupin Pharmaceuticals Inc.
D-0723-2026 - CGMP deviation

This Class II drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on June 23, 2026 for the product Glucagon. The FDA reported the reason for recall as cgmp deviation. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0723-2026

Reason for Recall
CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing.
Initiated
06-23-2026
Reported
07-08-2026
Quantity
64,894 units

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Lupin Pharmaceuticals Inc.
Nationwide within the U.S.
Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection USP, 1mg per vial, Diluent for Glucagon, 1 mL syringe, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur - 441108, INDIA, NDC 70748-311-01

Batch or Lot Expiration Information

Lot# Kit Lots: WB00010, Exp. Date Jan 2027; WB00017, WB00019, Exp. Date Feb 2027; WB00070, Exp. Date Jun 2027; WB00077, WB00078, Exp. Date Jul 2027; WB00130, Exp. Date Nov 2027.

Affected Packages Involved in this Recall